Neurological safety of fingolimod: An updated review

Fumihito Yoshii, Yusuke Moriya, Tomohide Ohnuki, Masafuchi Ryo and Wakoh Takahashi

1Department of Neurology, Saiseikai Hiratsuka Hospital, Hiratsuka, Japan, 2Department of Neurology, Tokai University Oiso Hospital, Oiso, Japan

Keywords
fingolimod; leukoencephalopathy; multiple sclerosis; neuromyelitis optica spectrum disorders; safety

Correspondence
Fumihito Yoshii, MD, Department of Neurology, Saiseikai Hiratsuka Hospital, 37-1 Tateno-cho, Hiratsuka 254-0046, Japan.
Tel: +81-463-31-0520
Fax: +81-463-31-3177
Emails: yoshii@is.icc.u-tokai.ac.jp and fu_yoshii67@yahoo.co.jp

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Received: 27 February 2017; revised: 23 April 2017; accepted: 8 May 2017.

Abstract
Fingolimod (FTY) is the first oral medication approved for treatment of relapsing–remitting multiple sclerosis (RRMS). Its effectiveness and safety were confirmed in several phase III clinical trials, but proper evaluation of safety in the real patient population requires long-term post-marketing monitoring. Since the approval of FTY for RRMS in Japan in 2011, it has been administered to approximately 5000 MS patients, and there have been side-effect reports from 1750 patients. Major events included infectious diseases, hepatobiliary disorders, nervous system disorders and cardiac disorders. In the present review, we focus especially on central nervous system adverse events. The topics covered are: (i) clinical utility of FTY; (ii) safety profile; (iii) post-marketing adverse events in Japan; (iv) white matter (tumefactive) lesions; (v) rebound after FTY withdrawal; (vi) relationship between FTY and progressive multifocal leukoencephalopathy; (vii) FTY and progressive multifocal leukoencephalopathy-related immune reconstitution inflammatory syndrome; and (viii) neuromyelitis optica and leukoencephalopathy.

Clinical utility of fingolimod
Fingolimod (FTY) is a sphingosine-1-phosphate receptor modulator that prevents egress of selected lymphocyte subsets (e.g. CCR7 positive-naïve T cells, central memory T cells) from lymph nodes, thereby reducing the number of lymphocytes in peripheral blood and their infiltration into the central nervous system.1,2 It is the first disease-modifying therapy (DMT) drug that can be orally administered, offering a clear advantage over other DMT drugs that must be injected daily (s.c., glatiramer acetate), every other day (s.c., interferon beta-1b [IFN-β1b]), weekly (i.m., IFN-β1a) or monthly (i.v., natalizumab [NTZ]).

Two large, phase III, double-blind, randomized trials have shown superior efficacy of FTY compared with placebo (2-year FREEDOMS and FREEDOMS II studies)3,4 or i.m. IFN-β1a (1-year TRANSFORMS and extended TRANSFORMS studies).5,6 FTY reduced the annualized relapse rate and slowed the progression of neurological disability in patients with relapsing–remitting multiple sclerosis (RRMS). Significant and sustained reductions in magnetic resonance imaging (MRI) lesion counts and brain volume loss have been reported in both short-term3,5 and long-term studies.6,7

Six randomized controlled trials of FTY versus placebo in RRMS patients who met various selection criteria showed that FTY 0.5 mg increased the probability of being relapse-free at 24 months (risk ratio [RR] 1.44, 95% CI 1.28–1.63), but in contrast, had little or no effect in preventing disability progression (RR 1.02, 95% CI 0.99–1.06).8 Benefit was also observed in terms of gadolinium-enhancing lesions in MRI (RR 1.36, 95% CI 1.27–1.45). The effects were similar to those of intramuscular IFN-β1a at 1 year: there was an increase in the number of patients free from relapse (RR 1.18, 95% CI 1.09–1.27) and decreased MRI-assessed activity (RR 1.12, 95% CI 1.05–1.19). However, inability to prevent or delay disability progression was confirmed (RR 1.02, 95% CI 0.99–1.06).
In Japan, clinical trials of once-daily FTY 0.5 mg or 1.25 mg for patients with RRMS showed a higher proportion of relapse-free patients and a reduction in the number of newly developed gadolinium-enhanced MRI lesions during a 6-month period, compared with the placebo. Additionally, the annualized relapse rate over 6 months was significantly reduced by FTY 0.5 mg and 1.25 mg versus the placebo, with relative reductions of 49% and 58%, respectively. Based on these results, once-daily oral FTY 0.5 mg (Gilenya, Novartis Pharma AG, Tokyo, Japan; or Imusera, Mitsubishi Tanabe, Osaka, Japan) was approved in September 2011 for the treatment of patients with RRMS, including those who failed to respond to first-line DMT.9,10

**Safety profile of fingolimod therapy**

The safety profile of FTY therapy has been carefully examined, particularly in the light of its anticipated long-term use. FTY was generally well tolerated in the aforementioned trials of up to 2 years' duration, with most adverse events (AE) being manageable and of mild-to-moderate severity.3,4,6 The cumulative datasets from clinical trials and their extensions, plus post-marketing studies, have well delineated the safety profile of FTY in patients with RRMS.11

The most common AE were cardiovascular events, including bradycardia and first-degree or second-degree atrioventricular block, after administration of the first dose.12 These AE usually occur within 1 h after administration of the drug, and bradycardia usually lasts for several days. In addition, a mild dose-dependent blood pressure increase over the course of 2 years was reported.

Because FTY causes a decrease of circulating lymphocytes, patients might be susceptible to serious infections, such as disseminated or central nervous system herpetic infection; indeed, two deaths were reported during the trial period as a result of primary disseminated varicella zoster infection and Herpes simplex encephalitis in the 1.25 mg/day group.5 Upper respiratory infections including nasopharyngitis or pharyngitis occurred in approximately 45% of patients in the Japanese clinical trial.9 Overseas trials found that the frequency of serious or opportunistic infection seems to be unrelated to lymphocyte count, and was not significantly increased even in patients whose lymphocyte counts had decreased to <200/mm³.3,13

Macular edema was confirmed in <1% of patients taking the currently approved dose (0.5 mg/day).1,5 It was mostly asymptomatic, though some patients complained of blurred vision or reduced visual acuity. Patients with diabetes mellitus have increased risk for onset of macular edema.

Localized skin cancer (basal-cell carcinoma and melanoma) and breast cancer were also reported,4 and a case of primary cutaneous T-cell lymphoma was recently reported in an MS patient treated with FTY.14 Throughout the core study and a 3-year phase 2 extension study in Japan, one case each of breast cancer and lymphoma were reported in patients receiving continuous FTY 0.5 mg/day.15 Further long-term follow-up study is required to clarify the risk of cancer.

Regarding laboratory test abnormalities, peripheral blood lymphocyte counts were reduced by approximately 75% from baseline after the first month.1,3,5 Mean lymphocyte counts began to rise within days of discontinuation, and reached the lower limit of normal by 4–8 weeks.16 Asymptomatic elevations in liver enzyme levels were seen more frequently.1,17 In the Japanese clinical trial, abnormal liver function was reported in 21.1% of the FTY 0.5 mg/day group and 33.3% of the FTY 1.25 mg/day group, mostly within 3 months after initiation of FTY.9 In general, the abnormal data reverted to the normal range after cessation of FTY.

**Post-marketing adverse events of fingolimod in Japan**

Since the marketing authorization of FTY 0.5 mg/day in Japan as an oral therapy for RRMS in November 2011, approximately 5175 patients have been treated in the 5 years until October 2016.18 With regard to AE, 1750 patients (33.8%) made some kind of report. Infections were most common (16.1%), followed by hepatobiliary disorders (16.0%), nervous system disorders (10.9%) and cardiac disorders (9.0%).18

The two major infections were Herpes zoster and nasopharyngitis, each accounting for 22% of all infections. There are reports of bronchitis in a small number of patients (6%). Liver dysfunction (elevated liver enzyme levels) accounted for 81% of hepatobiliary disorders. Although most nervous system disorders were reported to involve recurrence of MS lesions (23%), this might have included cases whose symptoms were worsened by FTY administration. This issue will be discussed in more detail below. Other nervous system symptoms included headache (16%) and dizziness (11%). Epileptic seizure was observed in <1% of all cases. Bradycardia
or atrioventricular block was observed in 4.3%, and macular edema was seen in <1.0%. Benign and malignant tumors have been reported in 31 patients, including four cervical adenocarcinoma, three gastric cancer, two cervical adenocarcinoma and two lymphoma. As for lymphopenia during treatment with FTY, 623 cases (18.2% of all cases reporting AE) were found.

**Fingolimod induced white matter (tumefactive) lesions**

Regarding neurological deterioration, there might have been some cases of MS relapse as a result of insufficient effect of FTY. However, there have been several case reports of paradoxically expanded inflammatory, demyelinating lesions. These lesions suggest that exacerbation can be divided into the multiple scattered type and space-occupying tumefactive type. Tumefactive-type lesions mimic tumors clinically and radiologically, and characteristically present large size (>2.0 cm) with a mass effect, edema and open ring enhancement. In general, the pathology of tumefactive lesions in the acute phase is characterized by massive demyelination associated with perivascular inflammation, reactive astrocytosis and infiltration of macrophages. In chronic lesions, demyelinated lesions with relative axonal preservation and sharply-defined margins were major findings.

It has been found that switching from other DMT to FTY can trigger tumefactive lesions in some MS patients. Development of these lesions indicates unusual activation of the immune system associated with FTY use. Table 1 summarizes some case reports where MS lesions were exacerbated after administration of FTY. The heterogeneity of these cases regarding disease duration, prior therapy, time to relapse on FTY, neurological symptoms and so on might be related to interindividual differences among patients with a susceptible immune constitution and sensitivity to FTY. Patients have been reported to suffer from confusion, dizziness and weakness, or to mimic neoplasm with symptoms such as headaches, aphasia and/or seizures. Diagnosis is commonly carried out using MRI, based on open ring enhancement in T1-weighted images with the use of gadolinium.

Tumefactive lesions usually accompany early MS attack, and are relatively rare in patients who have had MS for several years. However, FTY-induced tumefactive lesions often occur in patients with longstanding MS, suggesting that the medication causes a redistribution of immune cells. Because some patients developed these lesions soon after discontinuing the preceding DMT, it is unclear whether the cause of the lesions was starting FTY, stopping the other DMT or the combination of both. As the lesions occurred soon after switching to FTY therapy in some cases, it seems likely that FTY induced these lesions as a paradoxical effect.

How might FTY cause multiple extensive or tumefactive MS lesions? One possibility is that lymphocyte subsets in some patients treated with FTY might be shifted in a way that promotes MS disease activity. Pilz et al. observed changes in peripheral lymphocyte phenotypes, with a significant reduction in CD4+/CD8+ T-cell ratio.29 CD8+ effector cells in the central nervous system compartment can induce cytotoxicity through release of perforin, and might consequently induce the development of multiple scattered or tumefactive lesions. In contrast, Fuji et al. reported that the frequencies of CD56+ T cells and granzyme B-, perforin- and Fas ligand-positive T cells were significantly increased during FTY treatment, and each T cell subpopulation further increased during relapse.

It is important to be alert to the possibility that FTY can activate MS in some individuals. Unfortunately, up to now, no predictive features have been identified; hence, special caution is required at the initiation of FTY. No standard treatment exists, but high-dose intravenous corticosteroids (methylprednisolone 1 g for 3–5 days) followed by oral tapering hasten clinical and radiological improvement in approximately 80% of patients. Plasma exchange (PLEX) has been used in the absence of response to corticosteroids. Some patients with tumefactive demyelination refractory to corticosteroids or PLEX might still benefit from rituximab.

**Rebound after withdrawal of fingolimod**

In some patients, disease activity can surpass pretreatment activity shortly after discontinuation of FTY treatment, indicating a rebound effect. Such a rebound effect has previously been described after interruption of NTZ treatment. An analysis of >1800 patients who stopped NTZ therapy showed that relapse of disease activity was particularly evident in patients who had had highly active disease before NTZ therapy. Similarly, there are some case reports of exacerbation after discontinuation of FTY.

Patients with highly active disease before the start of treatment with FTY or who showed a good...
| No. | Author    | Year | Age (years) | Sex | MS type | Duration of MS (years) | Prior treatment (just before) | Time to relapse on FTY | FTY dose | MRI findings               | Relapse treatment | FTY continued | After Tx |
|-----|-----------|------|-------------|-----|---------|------------------------|-------------------------------|--------------------------|----------|------------------------------|------------------|---------------|---------|
| 1   | Leypoldt  | 2009 | 28          | F   | RRMS    | 4                      | Steroid                      | 7 months                 | 1.25 mg  | Ring, necrotic & hemorrhagic core | No               | Daclizumab (antibiotics) |
| 2   | Castrop   | 2012 | 26          | F   | RRMS    | 1.3                    | IFN-β1a IFN-β1b              | 6 weeks                  |          | Multiple active MS lesions     | PLEX             | No            | NTZ     |
| 3   | Daelman   | 2012 | 40          | F   | RRMS    | 23                     | NTZ                          | 11 days                  |          | Extensive active MS lesion      | IFN-β1b          | Yes           | NTZ     |
| 4   | Jander    | 2012 | 49          | M   | RRMS    | 2.3                    | NTZ                          | 8 weeks                  |          | Tumefactive                   | Steroid pulse    | Yes           | NTZ     |
| 5   | Visser    | 2012 | 23          | F   | RRMS    | 3.5                    | IFN-β                        | 4 months                 | 0.5 mg   | Tumefactive                   | IVMPI            | No            | GA      |
| 6   | Centonze  | 2012 | 25          | F   | RRMS    | 4                      | NTZ                          | 16 days                  |          | Multiple active MS lesions     | IVMPI            | Yes           | NTZ     |
| 7   | Centonze  | 2012 | 32          | F   | RRMS    | 6                      | NTZ                          | 19 days                  |          | Multiple active MS lesions     | IVMPI            | Yes           | NTZ     |
| 8   | Centonze  | 2012 | 25          | F   | RRMS    | 13                     | NTZ                          | 6 days                   |          | Multiple active MS lesions     | IVMPI            | Yes           | NTZ     |
| 9   | Centonze  | 2012 | 25          | F   | RRMS    | 13                     | NTZ                          | 6 days                   |          | Multiple active MS lesions     | IVMPI            | Yes           | NTZ     |
| 10  | Centonze  | 2012 | 25          | F   | RRMS    | 14                     | INF-β1b                      | 2 months, 14 months       |          | Tumefactive                   | IVMPI steroid     | No            | Steroid Rituximab |
| 11  | Totaro    | 2014 | 33          | F   | RRMS    | 6                      | NTZ                          | 13 months                |          | Tumefactive                   | IVMPI            | No            | NTZ     |
| 12  | Lindia    | 2015 | 38          | F   | RRMS    | 10                     | INF-β1a                     | 10 days                  |          | Active MS spinal cord lesion   | IVMPI            | Yes           | NTZ     |
| 13  | Endo      | 2015 | 46          | F   | RRMS    | 14                     | GA                           | 21 months 0.5 mg         |          | PRES                         | IVMPI            | Yes           | NTZ     |
| 14  | Harirchian| 2015 | 43          | M   | RRMS    | 4.5                    | INF-β1b                      | 18 weeks                 | 0.5 mg   | Multiple active MS lesions     | IVMPI steroid     | Yes           | NTZ     |
| 15  | Fragoso   | 2016 | 28          | F   | RRMS    | 3                      | NTZ                          | 20 months                |          | Tumefactive                   | IVMPI            | No            | NTZ     |
| 15  | Fragoso   | 2016 | 35          | F   | RRMS    | 2                      | NTZ                          | 15 months                |          | Tumefactive                   | IVMPI            | No            | NTZ     |

F, female; FTY, fingolimod; GA, glatiramer; INF, interferon; IVMPI, intravenous methylprednisolone treatment; M, male; NTZ, natalizumab; PLEX, plasma exchange; PRES, posterior reversible encephalopathy syndrome; RRMS, relapsing–remitting multiple sclerosis.
therapeutic response to FTY might be predisposed to severe rebound after withdrawal. A case of severe rebound of spinal cord MS activity after FTY withdrawal was also reported. Depressed peripheral lymphocyte counts increase to the normal range within 4–8 weeks after cessation. In accordance with this, several case reports have described rebound events approximately 2–4 months after stopping FTY. Overexpression of sphingosine-1-phosphate receptors in entrapped lymphocytes and massive egress of lymphocytes after FTY cessation, observed in animal models, seem to be plausible explanations for such an aggressive disease reactivation in some patients. Alternatively, differential changes of lymphocyte subset populations might play a role in rebound. As the absolute number of circulating Th17 cells decreased after FTY initiation in approximately 50% of patients, discontinuation of FTY could result in an increase in the number of circulating Th17 cells, leading to a rebound associated with reconstruction of the immune system.

Berger et al. reported that partial recovery was achieved after steroid pulse therapy followed by PLEX. However, most of the cases did not immediately respond to steroid. Serious, steroid-refractory neurological deterioration after FTY discontinuation can be treated with selective immune-adsorption therapy, which, unlike PLEX, is a column-based method for eliminating pathogenetically immune-relevant elements from plasma by using the binding properties of tryptophan.

Up to now, there have been no predictive factors defining this risk group. Therefore, patients should be informed about this potential effect after withdrawal, and closely monitored for several months after stopping FTY.

**Fingolimod and progressive multifocal leukoencephalopathy**

Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the central nervous system caused by reactivation of John Cunningham virus (JCV), and is a life-threatening condition. It occurs almost exclusively in patients with suppressed cell-mediated immunity, and is associated with the use of immunosuppressing medications, such as NTZ, in patients with MS. As of 7 September 2016, there have been 682 confirmed PML cases among NTZ users. Factors increasing the risk of PML in patients receiving NTZ include the presence of anti-JCV antibody in cerebrospinal fluid (CSF), the duration of treatment >2 years and prior treatment with immunosuppressive agents (azathioprine, methotrexate, cyclophosphamide etc.), all of which are now routinely considered before and during NTZ therapy.

Clinically, patients might present with symptoms suggestive of exacerbation of MS. However, PML should be ruled out when the clinical picture is different from typical MS exacerbation and suggests infection. PML often leads to progressive weakness, gait abnormalities, clumsiness, visual field defects, confusion, seizures, and changes in thinking, memory, orientation and personality.

Characteristic MRI features include one or more foci of T2/fluid-attenuated inversion recovery hyperintensity in a subcortical location involving U-fibers with an ill-defined border towards white matter. White matter involvement is typically peripheral, and lesions vary in shape and coalesce as they increase in size. Lesions >3 cm in size are more likely to be associated with PML than MS. As there is little inflammation pathologically, contrast enhancement is uncommon (approximately 30%). The lesions can occur virtually anywhere in the brain, but the frontal lobes and parieto-occipital regions appear to be most commonly affected.

The presence of JCV DNA in CSF as evidenced by polymerase chain reaction is required for a diagnosis of PML. However, because polymerase chain reaction testing for JCV antibody in CSF is limited in sensitivity, the JCV antibody index was introduced as a novel biomarker. Even in NTZ-treated anti-JCV antibody-positive MS patients with no prior immunosuppressant use, a higher anti-JCV antibody index can help to distinguish patients with an increased risk of PML.

The histopathology was characterized by a classical triad of multifocal demyelination, enlarged bizarre astrocytes with lobulated hyperchromatic nuclei and hyperchromatic, enlarged oligodendroglial nuclear inclusions, which signify the presence of JCV. Definite PML diagnosis requires these characteristic neuropathological features coupled with evidence of the presence of JCV by electron microscopy.

In an analysis of 336 MS patients taking NTZ who developed PML, factors associated with improved survival and clinical outcomes were younger age, less functional disability, low viral load in the CSF and more localized brain involvement by MRI. In general, the prognosis of MS patients with PML is better than that of patients with other underlying diseases, such as HIV infection or transplant recipient status, presumably because of the quick
immunological recovery on drug removal. Furthermore, the discrepancies in prognosis between the different categories of PML can probably be explained by their various degrees of immunosuppression. The more specifically the immune system is targeted (as in NTZ-induced PML), the better the prognosis in general. In contrast, if the immune system is suppressed as an intrinsic consequence of the disease process, such as PML as a result of HIV infection or hematological malignancies, the prognosis is generally poor.

If PML is suspected, the drug should be immediately discontinued and PLEX should be considered for the rapid removal of NTZ. However, Landi et al. recently reviewed a total of 193 international and 34 Italian NTZ-PML cases in the medical literature, and concluded that PLEX did not improve the survival or clinical outcome of patients with MS and NTZ-PML.

Fingolimod has become a common switch choice for patients previously taking NTZ. Initially, cases of PML during FTY treatment were identified among this group, so it was difficult to determine whether PML was related to FTY or was a “carry-over” effect of NTZ use. Among patients receiving FTY after previous NTZ treatment, there were 17 suspected cases of PML up to the end of 2015.

The first case of PML in a patient taking FTY, but not previously exposed to NTZ therapy, was identified in 2013. The patient was a 49-year-old man who developed probable PML after taking FTY for approximately 4 years. The patient had a 5-year history of MS, and had previously been treated with IFN-β1a for 10 months in addition to short-term corticosteroids, before and during FTY treatment. The second case was a 54-year-old man who developed PML after taking FTY for approximately 2.5 years. The patient had a 13- to 14-year history of MS, and had previously been treated with IFN-β1a for approximately 11 years, as well as with mesalazine for ulcerative colitis for the past 4 years. The third case, a 51-year-old woman with RRMS, was reported in 2015. She had been treated with FTY for 3 years, and the diagnosis of PML was made based on suggestive clinical symptoms, MRI findings and tests for JCV.

Through to September 2016, there have been nine probable or definite PML cases (including two cases from Japan) in the absence of any prior NTZ treatment. One patient developed PML 3 years after withdrawal of NTZ. All patients had been treated for at least 18 months (18–54 months). The risk has been estimated as 0.056/1000 patients (95% CI: 0.026–0.106).

No medications have proved consistently effective to treat FTY-PML in MS patients. Most patients should be treated with rapid removal of FTY by utilizing PLEX, as with cases of NTZ-PML. As the pathological pictures of PML are often mixed with PML-related immune reconstruction inflammatory syndrome (IRIS), some patients might be better treated with corticosteroids.

We suggest that FTY should be used with caution in patients with JCV-seropositive or high anti-JCV antibody index (>1.5). Patients who develop new neurological symptoms suggestive of PML should be urgently evaluated at very early stage and have expeditious MRI and JCV-polymerase chain reaction analysis.

### Fingolimod and progressive multifocal leukoencephalopathy-related immune reconstruction inflammatory syndrome

The use of NTZ to treat MS has been associated with the development of PML, but a new problem – IRIS – has emerged after cessation of NTZ (PML-related IRIS [PML-IRIS]). Clinical presentation is characterized by rapid worsening of previous neurological deficits as a result of an overwhelming immune response to JCV antigen, which leads to massive destruction of virus-infected and non-infected neuronal and glial tissues. Therefore, the onset of this syndrome is accelerated by PLEX, occurring in the majority of the patients within days to several weeks.

MRI shows an increase in size of pre-existing T2 fluid-attenuated inversion recovery lesions with either a patchy, punctate, irregular or ill-defined appearance in the border of the PML lesion with contrast enhancement. Contrast enhancement is the most common imaging sign suggestive of PML-IRIS, seen in 92.3% of patients. This is accompanied by increasing edema, cerebral swelling and mass effect, which are not typical of PML. Differentiation between PML-IRIS and rebound exacerbation of MS is usually possible by applying well-defined MRI criteria.

Autopsy showed massive cavitary lesions containing abundant perivascular and parenchymal CD8-positive T-cell infiltrates, and numerous macrophages within lesions. Plasma cells are also prominent as compared with typical MS lesions. It should be noted that, because PML-IRIS inevitably occurs after cessation of NTZ, most of the published pathological pictures represent mixtures of PML and PML-IRIS.

PML-IRIS itself causes significant morbidity and mortality, and is fatal in almost one-third of...
patients. The outcome of PML-IRIS was studied separately for patients before and after withdrawal/removal of NTZ. Patients with contrast enhancement of PML lesions on MRI at the time of diagnosis (early PML-IRIS) showed more severe symptoms and had worse Expanded Disability Status Scale scores at follow up than patients who developed contrast enhancement only after withdrawal/removal of NTZ (late PML-IRIS). That is, earlier onset was associated with greater residual disability. However, mortality was similar in the two groups (21.9 ± 11% vs 21.7 ± 8.8%).

To our knowledge, four cases of PML-IRIS during FTY treatment have been reported so far, and all were linked to prior NTZ therapy. Killestein et al. reported a 52-year-old RRMS male patient switched to FTY from NTZ as a result of a positive JCV antibody test. The patient presented with partial epileptic seizures of the left arm, followed by an increase in fatigue and difficulties in fine hand movements, as well as mild weakness of his left arm, initially interpreted as MS exacerbation. His lymphocyte count decreased together with close clinical and MRI monitoring. That is, earlier onset was associated with greater residual disability. However, mortality was similar in the two groups (21.9 ± 11% vs 21.7 ± 8.8%).

To our knowledge, four cases of PML-IRIS during FTY treatment have been reported so far, and all were linked to prior NTZ therapy. Killestein et al. reported a 52-year-old RRMS male patient switched to FTY from NTZ as a result of a positive JCV antibody test. The patient presented with partial epileptic seizures of the left arm, followed by an increase in fatigue and difficulties in fine hand movements, as well as mild weakness of his left arm, initially interpreted as MS exacerbation. His lymphocyte count decreased together with close clinical and MRI monitoring. That is, earlier onset was associated with greater residual disability. However, mortality was similar in the two groups (21.9 ± 11% vs 21.7 ± 8.8%).

Recently, maraviroc, a C-C chemokine-receptor type 5 antagonist, has shown promise in the prevention and treatment of NTZ-associated PML-IRIS. Unfortunately, to date, there are no biomarkers to predict the onset and severity of PML-IRIS.

Neuromyelitis optica and leukoencephalopathy

Neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) is a disabling autoimmune astrocytopathy characterized by severe and recurrent attacks of optic neuritis and longitudinally extensive myelitis. NMO is typically associated with a disease-specific serum NMO-immunoglobulin G antibody that selectively binds aquaporin-4 (AQP-4). Therefore, testing of antiAQP-4 antibody is essential, and is a most important laboratory finding for the diagnostic workup of suspected NMO. A new antigen target, myelin oligodendrocyte glycoprotein, was discovered recently and seems to be positive in approximately 20% of seronegative patients. However, its specificity needs to be evaluated more precisely in the future.

Therapy of NMO should be initiated as soon as the diagnosis is made. During acute attacks, high-dose i.v. methylprednisolone (1 g/day for 3–5 days) or, in some cases, PLEX was used. All patients are started on an immunosuppressive agent at the same time. Azathioprine and rituximab are suggested as a first-line treatment, and other immunosuppressive drugs, such as methotrexate, mycophenolate mofetil and mitoxantrone, are recommended as second-line treatments.

Fingolimod might exacerbate NMOSD. Min et al. reported a patient who developed extensive bilateral brain lesions during FTY treatment in the TRANSFORMS study. The initial diagnosis was MS, but after antiAQP-4 antibody was detected, it was changed to NMOSD. Brain MRI showed lesions predominantly involving the right frontal and parietal lobes, with vasogenic edema and enhancement. He had residual encephalomalacia and no recurrence with steroid treatment over 3 years after withdrawal of FTY.

We also reported a 54-year-old woman with leukoencephalopathy, mainly involving the cerebral white matter and brainstem, which occurred soon after switching to FTY from IFN-β1a therapy. She showed a relapsing–remitting course of optic neuritis and myelitis for 6 years. The patient was diagnosed initially as MS, but was recognized to be positive for antiAQP-4 antibody during FTY treatment. After discontinuation of FTY, the multiple lesions that appeared at the white matter and brainstem completely cleared concomitantly with clinical improvement. There are a few other case reports describing
the development of extensive brain lesions during FTY treatment in NMOSD patients.\textsuperscript{10,95,96}

Before starting FTY, the diagnosis of MS should be verified and, in any doubtful cases, particularly with opticospinal manifestations, antibodies to AQP-4 should be tested.

Conclusion

Fingolimod is a widely used medication for RRMS, and its oral route of administration is advantageous. The pivotal phase III trials showed that FTY is effective in comparison with placebo or IFN-β1a, and is generally well tolerated, but it remains necessary to accumulate further post-marketing data to assess its real-world safety profile.

Acknowledgments

We thank Mrs Isa Yoshinari at the Department of Neurology, Saiseikai Hiratsuka Hospital, for technical assistance. All authors hereby declare that submission of this manuscript for publication has been approved by Saiseikai Hiratsuka Hospital and Tokai University Oiso Hospital.

Conflict of interest

None declared.

References

1. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. \textit{N Engl J Med}. 2012; \textbf{366}: 339–47.
2. Ayzenberg I, Hoepner R, Kleiter I. Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. \textit{Ther Clin Risk Manag}. 2016; \textbf{12}: 261–72.
3. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. \textit{N Engl J Med}. 2010; \textbf{362}: 387–401.
4. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. \textit{Lancet Neurol}. 2014; \textbf{13}: 545–56.
5. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. \textit{N Engl J Med}. 2010; \textbf{362}: 402–15.
6. Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. \textit{J Neurol Neurosurg Psychiatry}. 2016; \textbf{87}: 468–75.
7. Radue EW, O’Connor P, Polman CH, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. \textit{Arch Neurol}. 2012; \textbf{69}: 1259–69.
8. La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G. Fingolimod for relapsing-remitting multiple sclerosis. \textit{Cochrane Database Syst Rev}. 2016; \textbf{4}: CD009371.
9. Saida T, Kikuchi S, Itoyama Y, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. \textit{Mult Scler}. 2012; \textbf{18}: 1269–77.
10. Kira J, Itoyama Y, Kikuchi S, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: result of a phase 2 observational extension. \textit{BMJ Neurol}. 2014; \textbf{14}: 21.
11. Kappos L, Cohen J, Collins W, et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. \textit{Mult Scler Relat Disord}. 2014; \textbf{3}: 494–504.
12. Laroni A, Brogi D, Morra VB, et al. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. \textit{BMJ Neurol}. 2014; \textbf{14}: 65.
13. Francis G, Kappos L, O’Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. \textit{Mult Scler}. 2014; \textbf{20}: 471–80.
14. Papatheoriki D, Gräfe R, Hildebrandt U, Zettl UK, Ulrich J. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. \textit{Mult Scler}. 2016; \textbf{22}: 1888–90.
15. Saida T, Itoyama Y, Kikuchi S, et al. Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study. \textit{BMJ Neurol}. 2017; \textbf{17}: 17.
16. Willis MA, Cohen JA. Fingolimod therapy for multiple sclerosis. \textit{Semin Neurol}. 2013; \textbf{33}: 37–44.
17. Khatri BO. Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. \textit{Ther Adv Neurol Disord}. 2016; \textbf{9}: 130–47.
18. https://drs-net.novartis.co.jp/dr/products/product/gilenya/. Accessed December 1, 2016.
19. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. \textit{Semin Immunopathol}. 2009; \textbf{31}: 439–53.
20. Sun C, Liu J, Gai Q, Lu D, Qi X. Analysis of pathological characteristics of acute and chronic cerebral tumefactive demyelinating lesions. \textit{Zhonghua Yi Xue Za Zhi}. 2014; \textbf{94}: 3557–61.
21. Leyboldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. \textit{Neurology}. 2009; \textbf{72}: 1022–4.
22. Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology. 2012; 78: 928–30.

23. Daelman L, Maitrot A, Maarouf A, Chaunu MP, Pepeix C, Tourbah A. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler. 2012; 18: 1647–9.

24. Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler. 2012; 18: 1650–2.

25. Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology. 2012; 79: 2000–3.

26. Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology. 2012; 79: 2004–5.

27. Kinney MO, McDonnell G. Re: Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology. 2013; 81: 403.

28. Yokoseki A, Saji E, Arakawa M, et al. Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy. Mult Scler. 2013; 19: 1230–3.

29. Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology. 2013; 81: 1654–8.

30. Hellmann MA, Lev N, Lotan I, et al. Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. J Neurol Sci. 2014; 344: 193–7.

31. Totaro R, Di Carmine C, Carolei A. Tumefactive demyelinating lesions in patients with relapsing remitting multiple sclerosis treated with fingolimod. J Neurol Neurophysiol. 2014; 512, http://doi.org/10.4172/2155-9562. S12-006.

32. Lindà H, von Hejne A. A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis. Front Neurol. 2015; 6: 39.

33. Endo H, Chihara N, Sekiguchi K, Kowa H, Kanda F, Toda T. A case of multiple sclerosis who relapsed early after fingolimod therapy introduced. Rinsho Shinkeigaku (Clin Neurol). 2015; 55: 417–20.

34. Harichian MH, Taalimi A, Siroos B. Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: a case report. Mult Scler Relat Disord. 2015; 4: 400–2.

35. Fragoso YD, Sato HK. Catastrophic magnetic resonance images in the central nervous system of patients undergoing treatment with fingolimod. CNS Neurosci Ther. 2016; 22: 633–5.

36. Paul F, Bourdette D. Tumefactive multiple sclerosis and fingolimod: immunotherapies and unintended consequences. Neurology. 2013; 81: 1648–9.

37. Lovera J, Villemarette-Pittman N. Tumefactive multiple sclerosis and fingolimod. J Neurol Sci. 2014; 344: 1–2.

38. Fujii C, Kondo T, Ochi H, et al. Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy. Sci Rep. 2016; 6: 35314.

39. Totaro R, Di Carmine C, Marini C, Carolei A. Tumefactive demyelinating lesions: spectrum of disease, diagnosis and treatment. Curr Neurobiol. 2016; 7: 21–6.

40. Ikeda KM, Lee DH, Fraser JA, Mirsattari S, Morrow SA. Plasma exchange in a patient with tumefactive, corticosteroid-resistant multiple sclerosis. Int J MS Care. 2015; 17: 231–5.

41. Sempere AP, Feliu-Rey E, Sanchez-Perez R, Nieto-Navarro J. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. J Neurol Neurosurg Psychiatry. 2013; 84: 1338–9.

42. O’Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011; 76: 1858–65.

43. Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpefl T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol. 2012; 69: 262–4.

44. Hakiki B, Portaccio E, Giannini M, Razzolini L, Pastò L, Amato MP. Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Mult Scler. 2012; 18: 1636–9.

45. Ghezzi A, Rocca MA, Baroncini D, et al. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J Neurol. 2013; 260: 327–9.

46. Beran RG, Hegazi Y, Schwartz RS, Cordato DJ. Rebound exacerbation multiple sclerosis following cessation of oral treatment. Mult Scler Relat Disord. 2013; 2: 252–5.

47. Sempere AP, Berenguer-Ruiz L, Feliu-Rey E. Rebound of disease activity during pregnancy after withdrawal of fingolimod. Eur J Neurol. 2013; 20: e109–10.

48. La Mantia L, Prone V, Marazzi MR, Erminio C, Protti A. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia. NeuroL Sci. 2014; 35: 1485–6.

49. Vecchio D, Naldi P, Stecco A, Cantello R, Leone MA. Severe rebound of spinal cord multiple sclerosis activity after fingolimod withdrawal. Clin Exp Neuroimmunol. 2014; 5: 378–9.

50. Alroughani R, Almulla A, Lamdhade S, Thussu A. Multiple sclerosis reactivation postfingolimod cessation: is it IRIS? BMJ Case Rep. 2014; bcr2014206314.

51. Berger B, Baumgartner A, Rauer S, et al. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J Neuroimmunol. 2015; 282: 118–22.

52. De Masi R, Accoto S, Orlando S, et al. Dramatic recovery of steroid-refractory relapsed multiple sclerosis following...
fingolimod discontinuation using selective immune adsorption. BMC Neurol. 2015; 15: 125.
53. Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord. 2015; 8: 233–8.
54. Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016; 73: 790–4.
55. Salam S, Mihalova T, Siripurapu R. Severe tumefactive rebound of multiple sclerosis following fingolimod cessation. BMJ Case Rep. 2016; 2016: bcr2016215596.
56. Gündüz T, Kürtüncü M, Er克斯oy M. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis. Mult Scler Relat Disord. 2017; 11: 1–3.
57. https://www.ms-supportnavi.com/ja-jp/home/med/tsy/safety/04.html. Accessed December 1, 2016.
58. Bloomsberg G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012; 366: 1870–80.
59. Igra MS, Palind D, Wattjes MP, Connolly DJA, Hoggard N. Multiple Sclerosis Update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. Br J Radiol. 2017; 90: 20160721.
60. Plavina T, Subramanyam M, Bloomsberg G, et al. Anti-JCV virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014; 76: 802–12.
61. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013; 80: 1430–8.
62. Dong-Si T, Gheuens S, Ganghadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol. 2015; 21: 637–44.
63. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011; 76: 1697–704.
64. Maas RP, Muller-Hansma AH, Esselinak RA, et al. Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol. 2016; 263: 2004–21.
65. Pavlovic D, Patera AC, Nyberg F, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015; 8: 255–73.
66. Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017; 88: 1144–52.
67. Dubeb D, Cano CA, Stouve O. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. Curr Opin Neurol. 2016; 29: 278–85.
68. https://www.fda.gov/Drugs/DrugSafety/ucm456919.htm. Accessed December 1, 2016.
69. Gyang TV, Hamel J, Goodman AD, Gross RA, Samkoff L. Fingolimod-associated PML in a patient with prior immunosuppression. Neurology. 2016; 86: 1843–5.
70. Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017; 12: 59–63.
71. Kanda T. Neuropathology of natalizumab-associated progressive multifocal leukoencephalopathy. Brain Nerve. 2015; 67: 891–901.
72. Cambron M, Hadhoum N, Duhin E, Lacour A, Chouraki A, Vermersch P. JCV serology in time: 3 years of follow-up. Acta Neurol Scand. 2017; 136: 54–8.
73. Hegen H, Auer M, Bsteh G, et al. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study. PLoS ONE. 2017; 12: e0174005.
74. Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 2012; 78: 1390–3.
75. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012; 71: 604–17.
76. Honce JM, Nagae L, Nyberg E. Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities. Mult Scler Int. 2015; 2015: 809252.
77. Purohit B, Ganewatte E, Kollias SS. Natalizumab-related progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome: a case report highlighting clinical and MRI features. Malays J Med Sci. 2016; 23: 91–5.
78. Wattjes MP, Wijburg MT, Vennegoor A, et al. Monitoring and future perspectives. Mult Scler Relat Disord. 2017; 5: 590–5.
79. Bauer J, Gold R, Adams O, Lassmann H. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). Acta Neuropathol. 2015; 130: 751–64.
80. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol. 2012; 123: 235–45.
81. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011; 77: 1061–7.
82. Killestein J, Vennegoor A, van Golde AE, Bourez RL, Wijlens ML, Wattjes MP. PML-IRIS during fingolimod discontinuation after natalizumab treatment. Case Rep Neurol Med. 2014; 2014: 307872.
83. Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. *J Clin Neurosci*. 2015; 22: 598–600.

84. N’gbo N’gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP. Immune-reconstitution inflammatory syndrome in multiple sclerosis patients treated with natalizumab: a series of 4 cases. *Clin Ther*. 2016; 38: 670–5.

85. Sinnecker T, Othman J, Kühl M, et al. Progressive multifocal leukoencephalopathy in a multiple sclerosis patient diagnosed after switching from natalizumab to fingolimod. *Case Rep Neurol Med*. 2016; 2016: 5876798.

86. Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. *JAMA Neurol*. 2014; 71: 436–41.

87. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. *Neurology*. 2014; 82: 1204–11.

88. Bsteh G, Auer M, Iglseder S, et al. Severe early natalizumab-associated PML in MS: effective control of PML-IRIS with maraviroc. *Neural Neuroimmunol Neuroinflamm*. 2017; 4: e323.

89. Hodecker SC, Stürner KH, Becker V, et al. Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. *Neural Neuroimmunol Neuroinflamm*. 2017; 4: e325.

90. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). *J Neurol*. 2014; 261: 1–16.

91. de Sèze J, Kremer L, Collongues N. Neuromyelitis optica spectrum disorder (NMOSD): a new concept. *Rev Neurol (Paris)*. 2016; 172: 256–62.

92. Crout TM, Parks LP, Majithia V. Neuromyelitis Optica (Devic’s syndrome): an appraisal. *Curr Rheumatol Rep*. 2016; 18: 54.

93. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. *Mult Scler*. 2012; 18: 113–5.

94. Yoshii F, Moriya Y, Ohnuki T, Ryo M, Takahashi W. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder. *Mult Scler Relat Disord*. 2016; 7: 53–7.

95. Izaki S, Narukawa S, Kubota A, Mitsui T, Fukaura H, Nomura K. A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment. *Rinsho Shinkeigaku (Clin Neurol)*. 2013; 53: 513–7.

96. Tanaka M, Oono M, Motoyama R, Tanaka K. Longitudinally extensive spinal cord lesion after initiation, and multiple extensive brain lesions after cessation of fingolimod treatment in a patient with recurrent myelitis and anti-aquaporin 4 antibodies. *Clin Exp Neuroimmunol*. 2013; 4: 239–40.